Loading
Cancer, Hypoxia, and Metabolism · Journal article
Clinical Pharmacology & Therapeutics · August 17, 2026
Raises a question worth testing. It does not answer one.
This is an early-phase hypothesis-generating study in 18 mCRPC patients showing that enzalutamide treatment induces sustained alterations in serum amino acid profiles, particularly taurine elevation, and that metabolomic changes at 3 months correlate with observed therapeutic response. The work combines clinical observation with in vitro mechanistic evidence but lacks prospective validation, independent cohort confirmation, or a pre-specified responder definition, so it raises the possibility of a predictive metabolomic signature rather than establishing one.
Uncontrolled, hypothesis-generating exploratory study with in vitro mechanistic validation. Patients with metastatic castrate-resistant prostate cancer treated with enzalutamide; specific site(s), inclusion/exclusion criteria, and baseline characteristics not stated.. Intervention: Enzalutamide 160 mg/day. n = 18.
Enzalutamide induced significant and sustained increase in several amino acids, with taurine displaying the most significant change. Serum metabolomic changes observed after 3 months of treatment were found to be significantly associated with pharmacological response. In vitro data suggest enzalutamide-induced elevation of systemic taurine results from both increased intestinal absorption and decreased hepatic extraction.
Serum metabolomic changes observed after 3 months of treatment were found to be significantly associated with pharmacological response.
This work suggests that host metabolic profiling during enzalutamide therapy might eventually guide personalised treatment decisions, but clinicians should not yet rely on metabolomic signatures for individual patient management. Further prospective validation in an independent cohort with pre-defined responder criteria is essential before any clinical application.
A small, single-centre, uncontrolled exploratory study with mechanistic in vitro validation that raises the question of whether metabolomic signatures predict enzalutamide response, but does not yet answer it with prospective validation or clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This work suggests that host metabolic profiling during enzalutamide therapy might eventually guide personalised treatment decisions, but clinicians should not yet rely on metabolomic signatures for individual patient management. Further prospective validation in an independent cohort with pre-defined responder criteria is essential before any clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Host metabolic changes in response to drug treatment may shape individual pharmacological outcomes. This study aims to identify serum metabolomics signatures potentially associated with individual responses to enzalutamide treatment in metastatic castrate-resistant prostate cancer (mCRPC) patients. Targeted metabolomic profiles in serum collected from 18 mCRPC patients treated with 160 mg/day of enzalutamide were measured at baseline, after 3 months of treatment, and until disease progression by a validated liquid chromatography tandem mass spectrometry analytical platform. The difference in the serum metabolomic profiles during enzalutamide treatment between good and poor responders was investigated by both multivariate and univariate statistical analysis. Primary mouse hepatocytes and Caco-2 cell models were employed to gain mechanistic insights into the most relevant changes detected. Enzalutamide induced a significant and sustained increase in several amino acids, with taurine displaying the most significant change. The in vitro data suggest that enzalutamide-induced elevation of systemic taurine results from both increased intestinal absorption and decreased hepatic extraction. Finally, serum metabolomic changes observed after 3 months of treatment were found to be significantly associated with the pharmacological response. This hypothesis-generating study reveals that enzalutamide significantly alters the host serum metabolome, inducing changes that correlate with therapeutic response over time. These results highlight the importance of host-drug metabolic interactions during androgen receptor inhibitor treatment and, although further validation is required, they support the hypothesis that metabolic profiling could eventually aid in the personalized management of enzalutamide therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.